SESSION TITLE: Pulmonary Vascular Disease: VTE
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: To evaluate the clinical application of warfarin dosing algorithm by VKORC1 and CYP2C9 genotypes in prediction of warfarin initial dose in patients with pulmonary thromboembolism.
METHODS: During March 2014 and July 2015,55 patients diagnosed with pulmonary embolism with/without deep venous thrombosis in the First Affiliated Hospital of Guangzhou Medical University were enrolled by the inclusion criteria. Those patients were randomly divided into a experimental group and a control group, including 25 and 30 cases respectively. 23 cases of 55 patients with male. The average age was (54.45±14.85). Classification of Pulmonary embolism low-risk (31), intermediate (19), high (5). In the experimental group, patients were detected the genotypes of VKORC1 and CYP2C9 When the first day of the diagnosis of pulmonary thromboembolism. Clinical laboratory doctor calculated the initial doses of warfarin. While in the control group, patients’warfarin therapy were performed by tradictional model. The frequency of INR monitoring was one time every day from the third day of initial warfarin therapy to leave hospital, one time every week after discharge, and one time every month after stable dose acquired, and the following-up lasted for 4 weeks.